In the week of November 24, the US Food and Drug Administration (FDA) issued a bold shot across the bow for the burgeoning consumer genomics industry. Issuing a letter to halt the genetic testing offered by 23andMe, perhaps the most prominent company of its kind, the agency has sent a clear message to the nascent sector: scale back, or be shut down.
But there is also a message that bears returning to the agency: regulating a 21st century technology with 20th century policy, no matter how well-intentioned, is liable to do more harm than good.
Read the full, original story here: A government ban on 23andMe’s genetic testing ignores reality
